Other languages iNtRON Biotechnology, Inc.

Equities

A048530

KR7048530000

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
6,520 ^KRW	-0.31%		-3.98%	-25.74%

13/03	INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/02	Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer	15/02
INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Bourse Zurich: les indices hésitent sur la direction à prendre avant la Fed	31/23/31
Bourse Zurich: le SMI reste dans le rouge avant la Fed	31/23/31
Bourse Zurich: ouverture en légère baisse avant la Fed	31/23/31
Morning Briefing - Markt Schweiz	31/23/31
Principales informations avant-Bourse	31/23/31
Basilea kauft Test-Lizenz für neuen Wirkstoff	31/23/31
Basilea prend une option sur un traitement antibactérien expérimental coréen	31/23/31
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON	31/23/31
INtRON Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
INtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome	30/23/30
INtRON Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15
INtRON Biotechnology, Inc. Confirms Cancer-Controlling Effect of Phageria Drug Candidate in the Organoid Model	04/23/04
INtRON Biotechnology, Inc. Confirms the Efficacy of BAL200, A Novel Endolysin Biologic for Inhalational Anthrax	26/23/26
INtRON Biotechnology, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	02/22/02
INtRON Biotechnology, Inc. authorizes a Buyback Plan.	02/22/02
INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14
INtRON Developed Advanced Bacteriophage Engineering Platform Technology Based on Modified Random Mutagenesis	18/22/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages iNtRON Biotechnology, Inc.

Equities

A048530

KR7048530000

Other languages

Filters